Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 36990-36998

  Chaikuad, Apirat ^a   Alfano, Ivan ^a   Kerr, Georgina ^a   Sanvitale, Caroline E ^a   Boergermann, Jan H ^b   Triffitt, James T ^a   Von Delft, Frank ^a   Knapp, Stefan ^a   Knaus, Petra ^b   Bullock, Alex N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE FORMATION; BONE MORPHOGENETIC PROTEINS; KINASE ACTIVATION; SMALL MOLECULE INHIBITOR; STRUCTURAL TEMPLATES;

BIOCHEMISTRY; BIOLOGY;

CHEMICAL ACTIVATION;

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FK 506 BINDING PROTEIN; PROTEIN FKBP12; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; OSSIFYING MYOSITIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE;

ACTIVIN RECEPTORS, TYPE I; AMINO ACID MOTIFS; ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUCIFERASES, FIREFLY; MICE; MODELS, MOLECULAR; MUTATION, MISSENSE; MYOSITIS OSSIFICANS; PROTEIN BINDING; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A;

EID: 84868249831     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.365932     Document Type: Article

References (51)

1. Shi, Y., and Massagué, J. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700
2. Kitisin, K., Saha, T., Blake, T., Golestaneh, N., Deng, M., Kim, C., Tang, Y., Shetty, K., Mishra, B., and Mishra, L. (2007) TGF-βa signaling in development. Sci. STKE 2007, cm1
3. Wu, M. Y., and Hill, C. S. (2009) TGF-β superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343
4. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. (1994) Mechanism of activation of the TGF-β receptor. Nature 370, 341-347
5. Heldin, C. H., Miyazono, K., and ten Dijke, P. (1997) TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471
6. Derynck, R., and Zhang, Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 425, 577-584
7. Wang, T., Li, B. Y., Danielson, P. D., Shah, P. C., Rockwell, S., Lechleider, R. J., Martin, J., Manganaro, T., and Donahoe, P. K. (1996) The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell 86, 435-444
8. Huse, M., Chen, Y. G., Massagué, J., and Kuriyan, J. (1999) Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96, 425-436
9. Huse, M., Muir, T. W., Xu, L., Chen, Y. G., Kuriyan, J., and Massagué, J. (2001) The TGFβ receptor activation process. An inhibitor-to substratebinding switch. Mol. Cell 8, 671-682
10. Qin, B. Y., Chacko, B. M., Lam, S. S., de Caestecker, M. P., Correia, J. J., and Lin, K. (2001) Structural basis of Smad1 activation by receptor kinase phosphorylation. Mol. Cell 8, 1303-1312
11. Wu, J. W., Hu, M., Chai, J., Seoane, J., Huse, M., Li, C., Rigotti, D. J., Kyin, S., Muir, T. W., Fairman, R., Massagué, J., and Shi, Y. (2001) Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by theMH2domain and insights on Smad function in TGF-β signaling. Mol. Cell 8, 1277-1289
12. Kaplan, F. S., Fiori, J., de la Peña, L. S., Ahn, J., Billings, P. C., and Shore, E. M. (2006) Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva. Ann. N.Y. Acad. Sci. 1068, 54-65
13. Shore, E. M., and Kaplan, F. S. (2010) Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 6, 518-527
14. Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T. J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M., Morhart, R., Rogers, J. G., Smith, R., Triffitt, J. T., Urtizberea, J. A., Zasloff, M., Brown, M. A., and Kaplan, F. S. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525-527
15. Furuya, H., Ikezoe, K., Wang, L., Ohyagi, Y., Motomura, K., Fujii, N., Kira, J., and Fukumaki, Y. (2008) A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am. J. Med. Genet. 146, 459-463
16. Kaplan, F. S., Xu, M., Seemann, P., Connor, J. M., Glaser, D. L., Carroll, L., Delai, P., Fastnacht-Urban, E., Forman, S. J., Gillessen-Kaesbach, G., Hoover-Fong, J., Köster, B., Pauli, R. M., Reardon, W., Zaidi, S. A., Zasloff, M., Morhart, R., Mundlos, S., Groppe, J., and Shore, E. M. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30, 379-390
17. Petrie, K. A., Lee, W. H., Bullock, A. N., Pointon, J. J., Smith, R., Russell, R. G., Brown, M. A., Wordsworth, B. P., and Triffitt, J. T. (2009) Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PloS ONE 4, e5005
18. Gregson,C.L.,Hollingworth,P.,Williams,M.,Petrie,K.A.,Bullock,A.N.,Brown, M. A., Tobias, J. H., and Triffitt, J. T. (2011) A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 48, 654-658
19. Bocciardi, R., Bordo, D., Di Duca, M., Di Rocco, M., and Ravazzolo, R. (2009) Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva. Confirmations and advancements. Eur. J. Hum. Genet. 17, 311-318
20. Whyte, M. P., Wenkert, D., Demertzis, J. L., DiCarlo, E. F., Westenberg, E., and Mumm, S. (2012) Fibrodysplasia ossificans progressiva. Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G3C, p.G325A) in ACVR1. J. Bone Miner. Res. 27, 729-737
21. Kan, L., Hu, M., Gomes, W. A., and Kessler, J. A. (2004) Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165, 1107-1115
22. Yu, P. B., Deng, D. Y., Lai, C. S., Hong, C. C., Cuny, G. D., Bouxsein, M. L., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C., Kamiya, N., Fukuda, T., Mishina, Y., Peterson, R. T., and Bloch, K. D. (2008) BMP type I receptor inhibition reduces heterotopic (corrected) ossification. Nat. Med. 14, 1363-1369
23. Wieser, R., Wrana, J. L., and Massagué, J. (1995) GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14, 2199-2208
24. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., and Olsen, B. R. (2010) Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406
25. Fukuda, T., Kanomata, K., Nojima, J., Kokabu, S., Akita, M., Ikebuchi, K., Jimi, E., Komori, T., Maruki, Y., Matsuoka, M., Miyazono, K., Nakayama, K., Nanba, A., Tomoda, H., Okazaki, Y., Ohtake, A., Oda, H., Owan, I., Yoda, T., Haga, N., Furuya, H., and Katagiri, T. (2008) A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem. Biophys. Res. Commun. 377, 905-909
26. Fukuda, T., Kohda, M., Kanomata, K., Nojima, J., Nakamura, A., Kamizono, J., Noguchi, Y., Iwakiri, K., Kondo, T., Kurose, J., Endo, K., Awakura, T., Fukushi, J., Nakashima, Y., Chiyonobu, T., Kawara, A., Nishida, Y., Wada, I., Akita, M., Komori, T., Nakayama, K., Nanba, A., Maruki, Y., Yoda, T., Tomoda, H., Yu, P. B., Shore, E. M., Kaplan, F. S., Miyazono, K., and Matsuoka, M., Ikebuchi, K., Ohtake, A., Oda, H., Jimi, E., Owan, I., Okazaki, Y., and Katagiri, T. (2009) Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J. Biol. Chem. 284, 7149-7156
27. Shen, Q., Little, S. C., Xu, M., Haupt, J., Ast, C., Katagiri, T., Mundlos, S., Seemann, P., Kaplan, F. S., Mullins, M. C., and Shore, E. M. (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J. Clin. Invest. 119, 3462-3472
28. Song, G. A., Kim, H. J., Woo, K. M., Baek, J. H., Kim, G. S., Choi, J. Y., and Ryoo, H. M. (2010) Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 285, 22542-22553
29. van Dinther, M., Visser, N., de Gorter, D. J., Doorn, J., Goumans, M. J., de Boer, J., and ten Dijke, P. (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 25, 1208-1215
30. Ohte, S., Shin, M., Sasanuma, H., Yoneyama, K., Akita, M., Ikebuchi, K., Jimi, E., Maruki, Y., Matsuoka, M., Namba, A., Tomoda, H., Okazaki, Y., Ohtake, A., Oda, H.,Owan,I.,Yoda,T.,Furuya,H.,Kamizono,J.,Kitoh,H.,Nakashima,Y.,Susami, T., Haga, N., Komori, T., and Katagiri, T. (2011) A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem. Biophys. Res. Commun. 407, 213-218
31. Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D., and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33-41
32. Leslie, A. G. (2006) The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57
33. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr.D Biol. Crystallogr. 62, 72-82
34. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674
35. Cowtan, K., and Main, P. (1998) Miscellaneous algorithms for density modification. Acta Crystallogr. D Biol. Crystallogr. 54, 487-493
36. Perrakis, A., Harkiolaki, M., Wilson, K. S., and Lamzin, V. S. (2001) ARP/ wARP and molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 57, 1445-1450
37. Cowtan, K. (2006) The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr.DBiol. Crystallogr. 62, 1002-1011
38. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255
39. Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132
40. Painter, J., and Merritt, E. A. (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450
41. Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray,L.W.,Arendall,W.B.,3rd,Snoeyink,J.,Richardson,J.S., andRichardson, D. C. (2007) MolProbity. All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383
42. Mueller, T. D., and Nickel, J. (2012) Promiscuity and specificity in BMP receptor activation. FEBS Lett. 586, 1846-1859
43. Lavery, K., Swain, P., Falb, D., and Alaoui-Ismaili, M. H. (2008) BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J. Biol. Chem. 283, 20948-20958
44. Wang, T., Donahoe, P. K., and Zervos, A. S. (1994) Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 265, 674-676
45. Han, S., Loulakis, P., Griffor, M., and Xie, Z. (2007) Crystal structure of activin receptor type IIB kinase domain from human at 2.0 Angstrom resolution. Protein Sci. 16, 2272-2277
46. Eswaran, J., Patnaik, D., Filippakopoulos, P., Wang, F., Stein, R. L., Murray, J. W., Higgins, J. M., and Knapp, S. (2009) Structure and functional characterization of the atypical human kinase haspin. Proc. Natl. Acad. Sci. U.S.A. 106, 20198-20203
47. Groppe, J. C., Wu, J., Shore, E. M., and Kaplan, F. S. (2011) In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194, 291-295
48. Hong, C. C., and Yu, P. B. (2009) Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 20, 409-418
49. Yin, S., Ding, F., and Dokholyan, N. V. (2007) Eris. An automated estimator of protein stability. Nat. Methods 4, 466-467
50. Le, V. Q., and Wharton, K. A. (2012) Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Dev. Dyn. 241, 200-214
51. Korchynskyi, O., and ten Dijke, P. (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem. 277, 4883-4891